On April 8, 2026, Vanda Pharmaceuticals Inc. unveiled the commencement of Thetis, a clinical trial investigating NEREUS™ (tradipitant) to prevent vomiting in patients undergoing treatment with glucagon-like peptide-1 (GLP-1) receptor agonist. Vanda, trading as VNDA on Nasdaq, shared this update, marking a significant step in the evaluation of this potential solution.